New experimental markers for early detection of high-risk prostate cancer: Role of cell-cell adhesion and cell migration

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 10, 2007, Pages 687-695

  Mol, A J M ^a   Geldof, A A ^a   Meijer, G A ^a   Van Der Poel, H G ^b   Van Moorselaar, R J A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Biological; Cell adhesion; Intercellular junctions; Neoplasm invasiveness; Neoplasm metastasis; Prognosis; Prostatic neoplasms; Review; Tumor markers

Indexed keywords

BETA CATENIN; FOCAL ADHESION KINASE; GAP JUNCTION PROTEIN; INTEGRIN; MATRIX METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; TUMOR MARKER; UVOMORULIN;

CANCER DIAGNOSIS; CANCER STAGING; CELL ADHESION; CELL COMMUNICATION; CELL MIGRATION; EXTRACELLULAR MATRIX; GAP JUNCTION; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CELL ADHESION; CELL MOVEMENT; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548235468     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0235-8     Document Type: Review

References (33)

1. Bonilla C, Mason T, Long L et al (2006) E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate 66:546-556
2. Boyer B, Valles AM, Edme N (2000) Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60:1091-1099
3. Chesire DR, Ewing CM, Gage WR, Isaacs WB (2002) In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21:2679-2694
4. Crawford ED (2003) Epidemiology of prostate cancer. Urology 62:3-12
5. Cress AE, Rabinovitz I, Zhu W, Nagle RB (1995) The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 14:219-228
6. Davis TL, Cress AE, Dalkin BL, Nagle RB (2001) Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate 46:240-248
7. Downward J (2004) PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15:177-182
8. Grunert S, Jechlinger M, Beug H (2003) Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4:657-665
9. Habermann H, Ray V, Habermann W, Prins GS (2002) Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 167:655-660
10. Horvath LG, Henshall SM, Lee CS et al (2005) Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 113:415-422
11. Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558
12. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC (2005) Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol Semin Original Invest 23:402-406
13. Jaggi M, Nazemi T, Abrahams NA, Baker JJ, Galich A, Smith LM, Balaji KC (2006) N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 66:193-199
14. Jonsson BA, Adami HO, Hagglund M, Bergh A, Goransson I, Stattin P, Wiklund F, Gronberg H (2004) -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 109:348-352
15. Klotz L (2006) Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol Semin Original Invest 24:46-50
16. Knudsen BS, Miranti CK (2006) The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem 99:345-361
17. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA (2003) The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 9:2185-2194
18. Li HC, Albert JM, Shinohara ET et al (2006) E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients. Urol Oncol Semin Original Invest 24:496-502
19. Mesnil M (2002) Connexins and cancer. Biol Cell 94:493-500
20. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC (2005) Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33:44-50
21. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003). Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661-668
22. Rovin JD, Frierson HF Jr, Ledinh W, Parsons JT, Adams RB (2002) Expression of focal adhesion kinase in normal and pathologic human prostate tissues. Prostate 53:124-132
23. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML (2001) E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Human Pathol 32:690-697
24. Sahai E (2005) Mechanisms of cancer cell invasion. Curr Opin Genet Dev 15:87-96
25. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM (2002) Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 167:103-111
26. Stewart DA, Cooper CR, Sikes RA (2004) Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2:2
27. Tate AW, Lung T, Radhakrishnan A, Lim SD, Lin X, Edlund M (2006) Changes in gap junctional connexin isoforms during prostate cancer progression. Prostate 66:19-31
28. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
29. Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S (1996) Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68:164-171
30. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B (2003) Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 63:8511-8515
31. Verhage BA, van HK, Ruijter TE, Kiemeney LA, Schalken JA (2002) Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 100:683-685
32. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME (1997) In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15:246-258
33. Yardy GW, Brewster SF (2005) Wnt signaling and prostate cancer. Prostate Cancer Prostatic Dis 8:119-126